Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John S Bomalaski
Polaris Group
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uhn - Princess Margaret Cancer Center (ontario)
Toronto, Ontario, Canada
- Mcgill University Health Centre (quebec)
Montreal, Quebec, Canada
- Chang Gung Medical Foundation Kaohsiung
Kaohsiung City, Niaosong District, Taiwan
- National Taiwan University Hospital
Taipei, Taipei, Taiwan
- Taipei Veterans General Hospital
Taipei, Taipei, Taiwan
- Mayo Clinic Arizona
Phoenix, Arizona, United States
- Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Stanford University Medical Centre
Palo Alto, California, United States
- Ucsf
San Francisco, California, United States
- Ucla
Santa Monica, California, United States
- University of Colorado Cancer Center/ Cu Anschutz Medical Campus
Aurora, Colorado, United States
- Mayo Clinic Florida
Jacksonville, Florida, United States
- University of Miami/ Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Northwestern
Chicago, Illinois, United States
- Indiana University
Indianapolis, Indiana, United States
- University of Iowa
Iowa City, Iowa, United States
- Mass General Brigham Cancer Center
Boston, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Nyu Langone Health
New York, New York, United States
- Duke Cancer Institute
Durham, North Carolina, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- Ohio State University Wexner Medical Center/ the James Cancer Hospital and Solove Research Institute
Columbus, Ohio, United States
- Upenn (abramson Cancer Center, Pennsylvania Hospital)
Philadelphia, Pennsylvania, United States
- Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Medical College of Wisconsin/ Froedtert Hospital
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Nov 2023
- Primary completion
- 25 May 2026
- Completion
- 25 May 2026
- Last update posted
- 25 Jun 2026
- Registered enrollment
- 218
- Registry id
- NCT05712694
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.